2. Search Result
Search Result
Results for "

AP

" in MedChemExpress (MCE) Product Catalog:

301

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

10

Peptides

1

Inhibitory Antibodies

33

Natural
Products

31

Recombinant Proteins

6

Isotope-Labeled Compounds

36

Antibodies

3

Click Chemistry

74

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161949
    AP-6

    		Potassium Channel Neurological Disease
    AP-6 is a selective inhibitor of TMEM175 with activity in modulating lysosomal function. Acute inhibition of TMEM175 by AP-6 increases lysosomal macromolecular catabolism, thereby accelerating macrophage and other digestive processes. AP-6 may be used in Parkinson's disease research .
    AP-6
  • HY-P1419
    AP 811

    		Natriuretic Peptide Receptor (NPR) Cardiovascular Disease
    AP 811 is a selective atrial natriuretic peptide clearance receptor (ANP-CR, NPR3) antagonist with a Ki of 0.48 nM. AP 811 displays >20000-fold selectivity for NPR3 over NPR1. AP 811 abolishes ANP-induced pump stimulation .
    AP 811
  • HY-W014421
    AP-18

    		TRP Channel Neurological Disease
    AP-18, a potent and selective TRPA1 inhibitor, blocks activation of TRPA1 by 50 μM Cinnamaldehyde with an IC50 of 3.1 μM and 4.5 μM for human and mouse TRPA1, respectively. AP-18 reverses complete Freund's adjuvant (CFA)-induced mechanical hyperalgesia in mice. AP-18 attenuated 30 μM AITC-induced Yo-Pro uptake in a concentration-dependent manner, with an IC50 of 10.3 μM .
    AP-18
  • HY-129363
    AP1867-3-(aminoethoxy)

    		Ligands for Target Protein for PROTAC FKBP Cancer
    AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader .
    AP1867-3-(aminoethoxy)
  • HY-126124
    AP39
    5 Publications Verification

    		 Reactive Oxygen Species Cardiovascular Disease Neurological Disease
    AP39 is a triphenylphosphonium derivatised anethole dithiolethione and mitochondria-targeting hydrogen sulfide (H2S) donor. AP39 increases intracellular H2S levels. AP39 exerts cytoprotective effects and maintains mitochondrial DNA integrity under oxidative stress conditions. AP39 protects against myocardial reperfusion injury in mice model and has the potential for Alzheimer's disease research .
    AP39
  • HY-162567
    AP-4-139B

    		HSP Cancer
    AP-4-139B is a heat shock protein 70 inhibitor (IC50=180 nM). HSP70 is a protein that is overexpressed in many types of cancer and is closely related to the survival and proliferation of tumor cells. AP-4-139B exhibits significant cytotoxicity to tumor cells, particularly in colorectal cancer cells. AP-4-139B can be used for cancer research .
    AP-4-139B
  • HY-170310
    AP-238

    		Opioid Receptor Neurological Disease
    AP-238 is a a new synthetic opioid (NSO), and acts as an agonist for μ-opioid receptor (MOR) with an EC50 of 248 nM. AP-238 exhibits analgesic activity .
    AP-238
  • HY-P1419A
    AP 811 acetate

    		Endothelin Receptor Cardiovascular Disease
    AP 811 acetate is a selective atrial natriuretic peptide clearance receptor (ANP-CR, NPR3) antagonist with a Ki of 0.48 nM. AP 811 acetate displays >20000-fold selectivity for NPR3 over NPR1. AP 811 acetate abolishes ANP-induced pump stimulation .
    AP 811 acetate
  • HY-P2434
    AP102

    		Somatostatin Receptor Neurological Disease Metabolic Disease Cancer
    AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC50: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .
    AP102
  • HY-169481
    AP-1

    		PROTACs Anaplastic lymphoma kinase (ALK) Cancer
    AP-1 is a PROTAC targeting anaplastic lymphoma kinase (ALK). AP-1 is composed of PROTAC target protein ligand CS-1243648 (HY-169482) (red part), E3 ligase ligand Pomalidomide (HY-10984) (blue part) and PROTAC Linker 2-(Tert-Butoxy)-2-oxoacetic acid (HY-W687662) (black part) .
    AP-1
  • HY-111220
    AP23846

    		Drug Derivative Others
    AP23846 is an active compound.
    AP23846
  • HY-105161
    AP-521 free base

    		5-HT Receptor Neurological Disease
    AP-521 (free base) is a benzothienopyridine derivative that exhibits potent anxiolytic effects by acting as a postsynaptic 5-HT1A receptor agonist and by enhancing serotonergic neural transmission in the medial prefrontal cortex (mPFC). AP-521 (free base) is promising for research of anxiety disorders .
    AP-521 free base
  • HY-112603A
    AP5 sodium

    		Free Fatty Acid Receptor Metabolic Disease
    AP5 sodium is a potent, orall active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 sodium demonstrates rat and human inositol monophosphate (IP1) EC50 values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 sodium has the potential for type II diabetes research .
    AP5 sodium
  • HY-112603
    AP5

    		Free Fatty Acid Receptor Metabolic Disease
    AP5 is a potent, orlly active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 demonstrates rat and human inositol monophosphate (IP1) EC50 values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 has the potential for type II diabetes research .
    AP5
  • HY-W059917
    AP24600

    		Drug Metabolite Others
    AP24600 is an inactive metabolite of Ponatinib .
    AP24600
  • HY-134368
    Ap3A

    		Calcium Channel Cardiovascular Disease
    Ap3A is a vasoactive molecule that regulates intracellular Ca 2+ levels. Ap3A can promote the growth of vascular smooth muscle cells .
    Ap3A
  • HY-12857
    Brigatinib
    25+ Cited Publications

    AP-26113

    		 Anaplastic lymphoma kinase (ALK) Cancer
    Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC .
    Brigatinib
  • HY-77101
    AP24592

    		Drug Metabolite Others
    AP24592 (M19) is an aromatic amine .
    AP24592
  • HY-129303
    AP219

    		Endogenous Metabolite Metabolic Disease
    AP39 (Item No. 17100) is a compound used to increase the levels of hydrogen sulfide (H2S) within mitochondria. It consists of a mitochondria-targeting motif (triphenylphosphonium) coupled to an H2S-donating moiety (dithiolethione) by an aliphatic linker. AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.
    AP219
  • HY-16046
    Rimiducid
    35+ Cited Publications

    AP1903

    		 FKBP Apoptosis Cancer
    Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.
    Rimiducid
  • HY-10363
    AP 24149

    		Bcr-Abl Src Cancer
    AP 24149 is a potent Src-Abl dual inhibitor with IC50 values of 9.1, 3.6 nM for Src and Abl, respectively .
    AP 24149
  • HY-134367
    Ap2A disodium

    		Adenosine Receptor PKA Apoptosis Cardiovascular Disease
    Ap2A (disodium) is a symmetrical dinucleoside polyphosphate. Ap2A (disodium) can promote the growth of vascular smooth muscle cells .
    Ap2A disodium
  • HY-153542
    AP-C6

    		PKG Others
    AP-C6 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C6 concentration-dependently inhibits human cGKII activity in vitro. AP-C6 potentiate cAMP signaling by PDE inhibition .
    AP-C6
  • HY-160045
    AP1153 aptamer sodium

    		Cholecystokinin Receptor Cancer
    AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .
    AP1153 aptamer sodium
  • HY-125064
    AP22408

    		Src Cancer
    AP22408 is a nonpeptide inhibitor against Src SH2 with an IC50 value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .
    AP22408
  • HY-120355A
    AP14145 hydrochloride

    		Potassium Channel Cardiovascular Disease
    AP14145 hydrochloride is a potent KCa2 (SK) channel negative allosteric modulator with an IC50 of 1.1 μM for KCa2.2 (SK2) and KCa2.3 (SK3) channels. AP14145 hydrochloride inhibition strongly depends on two amino acids, S508 and A533 in the channel. AP14145 hydrochloride prolonged atrial effective refractory period (AERP) in rats and demonstrates antiarrhythmic effects in a Vernakalant-resistant porcine model of atrial fibrillation (AF) .
    AP14145 hydrochloride
  • HY-134370
    Ap4G

    		P2X Receptor Cardiovascular Disease
    Ap4G is a dinucleoside polyphosphate compound with vasoconstrictor activity. Ap4G regulates vasoconstriction through P2 receptors, especially P2X receptors, and is an important tool for studying vascular physiology and pathology .
    Ap4G
  • HY-157557
    AP30663

    		Potassium Channel Cardiovascular Disease
    AP30663 is a KCa2 channel inhibitor that can be used for the study of atrial fibrillation .
    AP30663
  • HY-114434
    AP1867
    3 Publications Verification

    		 FKBP Cancer
    AP1867 is a synthetic FKBP12 F36V-directed ligand .
    AP1867
  • HY-100166
    AP521

    		5-HT Receptor Neurological Disease
    AP521 is an agonist of human 5-HT1A receptor with an IC50 of 94 nM.
    AP521
  • HY-153540
    AP-C4

    		PKG Others
    AP-C4 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.2. AP-C3 does not inhibit cGKII-dependent anion secretion .
    AP-C4
  • HY-10638
    AP23464

    		c-Kit Apoptosis Cancer
    AP23464 is an ATP-based inhibitor for Kit, that inhibits the phosphorylation of Kit wildtype and mutants, with IC50 of 5-85 nM. AP23464 inhibits the proliferation of Kit mutated cells (IC50 is 3-20 nM), arrests the cell cycle at G0/G1 phase, and induces apoptosis in Kit mutated cells .
    AP23464
  • HY-153541
    AP-C7

    		PKG Others
    AP-C7 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.0. AP-C7 only weakly inhibits cGKII-dependent anion secretion .
    AP-C7
  • HY-153539
    AP-C3

    		PKG Others
    AP-C3 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.3. AP-C3 only weakly inhibits cGKII-dependent anion secretion .
    AP-C3
  • HY-153537
    AP-C1

    		PKG Others
    AP-C1 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C1 only weakly inhibits cGKII-dependent anion secretion .
    AP-C1
  • HY-134369
    Ap4C tetrasodium

    		P2Y Receptor Others Inflammation/Immunology
    Ap4C tetrasodium is a dinucleoside polyphosphate containing purine and pyrimidine base moieties. Ap4C tetrasodium acts as a signaling molecule by binding to specific P2Y receptors, activating P2Y2 and P2Y4 receptors in platelets, leading to platelet aggregation and other cellular responses. Ap4C tetrasodium can be used for research in inflammation and blood coagulation .
    Ap4C tetrasodium
  • HY-15858
    AP-III-a4
    5+ Cited Publications

    ENOblock

    		 Enolase Apoptosis Metabolic Disease Cancer
    AP-III-a4 (ENOblock) is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 can be used for the research of cancer and diabetic .
    AP-III-a4
  • HY-15858A
    AP-III-a4 hydrochloride
    5+ Cited Publications

    ENOblock hydrochloride

    		 Enolase Apoptosis Metabolic Disease Cancer
    AP-III-a4 (ENOblock) hydrochloride is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 hydrochloride can be used for the research of cancer and diabetic .
    AP-III-a4 hydrochloride
  • HY-133987
    AP-1/NF-κB activation inhibitor 1
    1 Publications Verification

    		 NF-κB Inflammation/Immunology
    AP-1/NF-κB activation inhibitor 1 is a potent AP-1 and NF-κB mediated transcriptional activation inhibitor (IC50=1 μM), without blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells .
    AP-1/NF-κB activation inhibitor 1
  • HY-12857S2
    Brigatinib-d11

    AP-26113-d11

    		 Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Cancer
    Brigatinib-d11 (AP-26113-d11) is deuterium labeled Brigatinib. Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC .
    Brigatinib-d11
  • HY-120355
    AP14145

    		Potassium Channel Cardiovascular Disease
    AP14145 is an inhibitor for small conductance calcium-activated potassium channel, inhibits KCa2.2 channel and KCa channel with IC50 of 1.1 μM and 1.1 μM. AP14145 prolongs atrial effective refractory period (AERP) in rats, causes the conversion of atrial fibrillation to sinus rhythum in porcine left ventricular dysfunction models, and exhibits antiarrhythmic effect .
    AP14145
  • HY-107458
    AP23848

    		c-Kit Cancer
    AP23848 is an ATP-dependent kinase inhibitor that effectively and selectively targets the Kit activation loop mutation both in vitro and in vivo, showing anti-tumor activity. AP23848 can inhibit the phosphorylation of the activated Kit mutation and tumor growth in mice, making it suitable for targeting diseases with the D816V mutation, such as systemic mastocytosis (SM) and acute myeloid leukemia (AML) research .
    AP23848
  • HY-156214
    NICE-01

    AP1867-PEG2-JQ1; AP-PEG2-JQ1

    		 Epigenetic Reader Domain Others
    NICE-01 (AP1867-PEG2-JQ1; AP-PEG2-JQ1) is a bifunctional compound that bind to proteins in separate cellular compartments that can induce nuclear import of cytosolic cargoes, using nuclear-localized bromodomain-containing protein 4 (BRD4) as a “carrier” for co-import and nuclear trapping of cytosolic proteins .
    NICE-01
  • HY-115832
    Ap44mSe

    		Transferrin Receptor Cancer
    Ap44mSe is a selenosemicarbazone that effectively depletes cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1. Ap44mSe forms redox active Cu complexes that target the lysosome to induce lysosomal membrane permeabilization .
    Ap44mSe
  • HY-130530
    AP-C5

    		Biochemical Assay Reagents Metabolic Disease
    AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AP-C5
  • HY-142118
    Trabedersen

    AP 12009

    		 TGF-beta/Smad Cancer
    Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2, such as those of the skin, pancreas and colon .
    Trabedersen
  • HY-168345
    Ap4dT

    		DNA/RNA Synthesis Others
    Ap4dT is an inhibitor for human adenylate kinase isozyme 1 (hAK1), that inhibits the ATP and ADP synthesis with IC50s of 42 μM and 38 μM .
    Ap4dT
  • HY-153538
    AP-C2

    		Ser/Thr Protease Metabolic Disease
    AP-C2 is a potent guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) inhibitor with a pIC50 of 5.2 .
    AP-C2
  • HY-114420
    AP1867-2-(carboxymethoxy)
    1 Publications Verification

    PROTAC FKBP12-binding moiety 2

    		 FKBP Ligands for Target Protein for PROTAC Cancer
    AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12 F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules .
    AP1867-2-(carboxymethoxy)
  • HY-RS00785
    AP2A2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    AP2A2 Human Pre-designed siRNA Set A contains three designed siRNAs for AP2A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AP2A2 Human Pre-designed siRNA Set A
    AP2A2 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: